1. Home
  2. SPRY vs DCTH Comparison

SPRY vs DCTH Comparison

Compare SPRY & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ARS Pharmaceuticals Inc.

SPRY

ARS Pharmaceuticals Inc.

N/A

Current Price

$5.90

Market Cap

634.5M

Sector

Health Care

ML Signal

N/A

DCTH

Delcath Systems Inc.

N/A

Current Price

$16.35

Market Cap

578.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SPRY
DCTH
Founded
2015
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
634.5M
578.4M
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
SPRY
DCTH
Price
$5.90
$16.35
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$40.00
$22.00
AVG Volume (30 Days)
1.7M
702.7K
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
107.53
EPS
N/A
0.04
Revenue
$84,278,000.00
N/A
Revenue This Year
$87.40
$24.54
Revenue Next Year
$81.64
$33.15
P/E Ratio
N/A
$409.75
Revenue Growth
N/A
N/A
52 Week Low
$4.91
$8.12
52 Week High
$13.15
$17.42

Technical Indicators

Market Signals
Indicator
SPRY
DCTH
Relative Strength Index (RSI) 47.54 58.70
Support Level $4.96 $8.57
Resistance Level $6.58 $17.42
Average True Range (ATR) 0.38 0.54
MACD 0.09 -0.15
Stochastic Oscillator 61.08 14.96

Price Performance

Historical Comparison
SPRY
DCTH

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: